As the many COVID-19 vaccines under development barrel toward clinical trials for safety and efficacy (see infographic, p. 3), questions remain about how they will be distributed when they become available. Payers and PBMs will likely play a critical role in vaccine rollout, but what that will entail is not yet clear. In large part, that’s because both the health insurance industry and pharmaceutical manufacturers are waiting on a vaccine distribution plan from the federal government.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.